for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

AnaptysBio Inc

ANAB.OQ

Latest Trade

41.21USD

Change

-0.54(-1.29%)

Volume

321,483

Today's Range

40.70

 - 

42.25

52 Week Range

38.59

 - 

110.00

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
41.75
Open
41.05
Volume
321,483
3M AVG Volume
6.59
Today's High
42.25
Today's Low
40.70
52 Week High
110.00
52 Week Low
38.59
Shares Out (MIL)
27.05
Market Cap (MIL)
1,129.24
Forward P/E
-9.86
Dividend (Yield %)
--

Next Event

AnaptysBio Inc at Cantor Fitzgerald Global Healthcare Conference

Latest Developments

More

AnaptysBio Inc Says CFO Dominic Piscitelli To Resign, Effective As Of September 9

Anaptysbio Q2 Loss Per Share $0.89

AnaptysBio Presents Updated Data From Etokimab Phase 2a Proof-Of-Concept Clinical Trial In Severe Eosinophilic Asthma

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About AnaptysBio Inc

AnaptysBio, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Its product pipeline includes ANB020 and ANB019, which are being developed to treat severe inflammatory disorders with unmet medical need. The Company's ANB020 product candidate is an antibody that inhibits the activity of interleukin-33, and is used for the treatment of severe adult asthma and severe adult peanut allergy. In addition, the Company is engaged in developing its ANB019 product candidate, an antibody that inhibits the interleukin-36 receptor, for the treatment of rare inflammatory diseases called generalized pustular psoriasis (GPP) and palmoplantar pustular psoriasis (PPP).

Industry

Biotechnology & Drugs

Contact Info

10421 Pacific Center Ct Ste 200

+1.858.3626295

https://www.anaptysbio.com/

Executive Leadership

Hamza Suria

President, Chief Executive Officer, Director

Dominic G. Piscitelli

Chief Financial Officer

Eric Joseph Loumeau

Interim Chief Financial Officer, General Counsel

Marco Londei

Chief Medical Officer

Hollings C. Renton

Lead Independent Director

Key Stats

2.00 mean rating - 10 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-1.620

2017

-1.520

2018

-2.500

2019(E)

-4.236
Price To Earnings (TTM)
--
Price To Sales (TTM)
112.92
Price To Book (MRQ)
2.52
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
1.07
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-21.39
Return on Equity (TTM)
-20.10

Latest News

BRIEF-Anaptysbio Qtrly Loss Per Share $0.63

* ANAPTYSBIO ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES PIPELINE UPDATES

BRIEF-Anaptysbio Announces Positive Top-Line Proof-Of-Concept Data For ANB020 In Moderate-To-Severe Baseline Adult Peanut Allergy Patients

* ANAPTYSBIO ANNOUNCES POSITIVE TOP-LINE PROOF-OF-CONCEPT DATA FOR ANB020 IN MODERATE-TO-SEVERE BASELINE ADULT PEANUT ALLERGY PATIENTS

BRIEF-AnaptysBio Qtrly ‍Loss Per Share $0.30

* ANAPTYSBIO ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND 2018 PIPELINE MILESTONES

BRIEF-Anaptysbio qtrly loss per share $0.45

* Anaptysbio announces third quarter 2017 financial results and provides pipeline updates

BRIEF-AnaptysBio reports positive ANB019 top-line phase 1 clinical trial results

* Anaptysbio reports positive anb019 top-line phase 1 clinical trial results

BRIEF-AnaptysBio prices public offering of 3 mln shares at $68.50 per share

* Says public offering of 3.00 million common shares priced at $68.50per share Source text for Eikon: Further company coverage:

BRIEF-AnaptysBio reports positive data from phase 2A clinical trial of ANB020 in atopic dermatitis

* AnaptysBio reports positive topline proof-of-concept data from phase 2A clinical trial of ANB020 in atopic dermatitis

BRIEF-‍adage Capital reports a 6.05 percent passive stake in AnaptysBio

* Adage Capital Partners GP reports a 6.05 percent passive stake in AnaptysBio Inc as of September 22 - SEC filing Source text: (http://bit.ly/2yTdILI) Further company coverage:

BRIEF-AnaptysBio reports about 19 pct rise in Q2 revenue

* AnaptysBio announces second quarter 2017 financial results and provides pipeline updates

BRIEF-AnaptysBio qtrly net loss per common share $0.75

* AnaptysBio announces first quarter 2017 financial results and provides pipeline update

BRIEF-Anaptysbio plans to seek regulatory clearance to initiate phase 2 studies of anb019

* Anaptysbio Inc- plans to seek regulatory clearance to initiate phase 2 studies of anb019 in patients with gpp and ppp during 2018

BRIEF-Anaptysbio FY loss per share $1.62

* FY loss per share $1.62 Source text for Eikon: Further company coverage:

BRIEF-Frazier Healthcare V, L.P reports 18.5 pct stake in Anaptysbio as of Jan. 31, 2017 - SEC filing

* Frazier Healthcare V, L.P reports 18.5 percent stake in Anaptysbio Inc as of January 31, 2017 - SEC filing Source text - (http://bit.ly/2kR6ZeE) Further company coverage:

BRIEF-BVF PARTNERS L.P. REPORTS 9.6 PCT PASSIVE STAKE IN ANAPTYSBIO INC

* BVF PARTNERS L.P. REPORTS A 9.6 PERCENT PASSIVE STAKE IN ANAPTYSBIO INC AS OF JAN 26, 2017- SEC FILING Source text - http://bit.ly/2k5fK3H Further company coverage:

BRIEF-AnaptysBio Inc shares open at $16.00 in debut, above IPO price of $15.00 per share

* AnaptysBio Inc shares open at $16.00 in debut, above IPO price of $15.00 per share Further company coverage:

BRIEF-AnaptysBio prices IPO of 5 mln shares at $15 per share

* Says initial public offering of 5.00 million common shares priced at $15.00 per share Source text for Eikon: Further company coverage:

BRIEF-AnaptysBio Inc sees IPO of 4 mln shares

* Anaptysbio Inc sees its IPO 4 million shares priced between $14.00 and $16.00 per share Source text (http://bit.ly/2jrOz5X) Further company coverage:

BRIEF-Anaptysbio announces the appointment of Dominic Piscitelli as CFO

* Anaptysbio announces the appointment of Dominic Piscitelli as chief financial officer Source text for Eikon: Further company coverage:

BRIEF-AnaptysBio reports ANB020 top-line early-stage clinical trial results

* Reports ANB020 top-line phase 1 clinical trial results; favorable safety and pharmacodynamic parameters demonstrated in healthy volunteers

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up